Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus.

Li FY, Chaigne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ.

Blood. 2014 Apr 3;123(14):2148-52. doi: 10.1182/blood-2013-11-538686. Epub 2014 Feb 18. Review.

2.

[Current status and future prospects of stem cell gene therapy for primary immunodeficiency].

Uchiyama T, Onodera M.

Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(3):148-55. Review. Japanese.

3.

Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities.

Hendriks WJ, Pulido R.

Biochim Biophys Acta. 2013 Oct;1832(10):1673-96. doi: 10.1016/j.bbadis.2013.05.022. Epub 2013 May 23. Review.

4.

Gene therapy for PIDs: progress, pitfalls and prospects.

Mukherjee S, Thrasher AJ.

Gene. 2013 Aug 10;525(2):174-81. doi: 10.1016/j.gene.2013.03.098. Epub 2013 Apr 6. Review.

5.

Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency.

Agarwal S, Mayer L.

Clin Gastroenterol Hepatol. 2013 Sep;11(9):1050-63. doi: 10.1016/j.cgh.2013.02.024. Epub 2013 Mar 13. Review.

6.

Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.

Liao W, Lin JX, Leonard WJ.

Immunity. 2013 Jan 24;38(1):13-25. doi: 10.1016/j.immuni.2013.01.004. Review.

7.

Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.

Wu C, Dunbar CE.

Front Med. 2011 Dec;5(4):356-71. doi: 10.1007/s11684-011-0159-1. Epub 2011 Dec 27. Review.

8.

IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation.

Liao W, Lin JX, Leonard WJ.

Curr Opin Immunol. 2011 Oct;23(5):598-604. doi: 10.1016/j.coi.2011.08.003. Epub 2011 Aug 31. Review.

9.

Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy.

Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J.

Clin Exp Immunol. 2011 Jun;164 Suppl 2:2-5. doi: 10.1111/j.1365-2249.2011.04387.x. Review.

10.

Genotoxicity of retroviral hematopoietic stem cell gene therapy.

Trobridge GD.

Expert Opin Biol Ther. 2011 May;11(5):581-93. doi: 10.1517/14712598.2011.562496. Epub 2011 Mar 7. Review.

11.

Contributions of gene marking to cell and gene therapies.

Barese CN, Dunbar CE.

Hum Gene Ther. 2011 Jun;22(6):659-68. doi: 10.1089/hum.2010.237. Epub 2011 May 5. Review.

12.

The use of structural biology in Janus kinase targeted drug discovery.

Alicea-Velázquez NL, Boggon TJ.

Curr Drug Targets. 2011 Apr;12(4):546-55. Review.

13.

X-Linked Severe Combined Immunodeficiency.

Allenspach E, Rawlings DJ, Scharenberg AM.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015.
2003 Aug 26 [updated 2013 Jan 24].

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk